GNFT Key Statistics, Chart & Performance
The current stock price of GNFT is 4.85 USD. In the past month the price increased by 12.79%. In the past year, price increased by 15.48%.
GNFT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About GNFT
Company Profile
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Company Info
GENFIT-ADR
Parc Eurasante 885 avenue Eugene Avinee
LOOS HAUTS-DE-FRANCE 59120 FR
CEO: Pascal Prigent
Employees: 188
Phone: 33320164000
GENFIT-ADR / GNFT FAQ
What does GNFT do?
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
What is the current price of GNFT stock?
The current stock price of GNFT is 4.85 USD. The price increased by 2.54% in the last trading session.
What is the dividend status of GENFIT-ADR?
GNFT does not pay a dividend.
What is the ChartMill rating of GENFIT-ADR stock?
GNFT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting GNFT stock to perform?
13 analysts have analysed GNFT and the average price target is 9.84 USD. This implies a price increase of 102.95% is expected in the next year compared to the current price of 4.85.
Would investing in GENFIT-ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GNFT.
GNFT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to GNFT. When comparing the yearly performance of all stocks, GNFT is one of the better performing stocks in the market, outperforming 78.34% of all stocks.
GNFT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNFT. GNFT may be in some trouble as it scores bad on both profitability and health.
GNFT Financial Highlights
Over the last trailing twelve months GNFT reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS decreased by -289.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.89% | ||
| ROE | -73.87% | ||
| Debt/Equity | 0.09 |
GNFT Forecast & Estimates
13 analysts have analysed GNFT and the average price target is 9.84 USD. This implies a price increase of 102.95% is expected in the next year compared to the current price of 4.85.
For the next year, analysts expect an EPS growth of -192.65% and a revenue growth -34.41% for GNFT